Switzerland-based Biocartis SA has raised €34.5 million in a Series D round to commercialise a molecular diagnostics platform that is aimed at the life science research market. The round was led by the Flemish investment company, PMV NV. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
